Study: Most drug products recouped development costs within a decade of approval
Regulatory NewsJeff Craven
Approval/marketing authorizationBiologics License Application (BLA)Biologics/ biosimilars/ vaccinesNew Drug Application (NDA)Orphan drugsPDUFAPharmaceuticalsProduct developmentReimbursementUnited StatesUS Food and Drug Administration (FDA)